Marshall Fordyce

CEO Marshall Fordyce sold 18,500 shares ($701.8K) at VERA via scheduled 10b5-1 plan on 2026-06-23.

Marshall Fordyce, President and CEO, executed 2 separate sales totaling 18,500 shares for $701,769.25 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-01-09, reducing his holdings from 216,744 shares to 198,244 shares. The company reported net income of -$121,032,000 for its most recent full fiscal year and currently trades at $39.51, down 29.5% from its 52-week high of $56.05. Fordyce's prior trades at VERA have resulted in average 30-day declines of -8.2% to -13.1%, though these scheduled sales reflect pre-determined execution rather than discretionary timing decisions. Given the company's unprofitability, the ongoing scheduled nature of the plan adopted in January, and the CEO's continued material stake of 198,244 shares post-transaction, this filing merits monitoring for whether subsequent disclosures signal changes in the company's operational trajectory.

VERA President and CEO Fordyce Marshall sells ~18,500 shares for $680K as stock trades well below its 52-week high; all five prior VERA sales saw subsequent declines.

Fordyce Marshall, President and CEO of Vera Therapeutics, is liquidating equity with this sale of approximately 18,500 shares, reducing his stake by roughly 8%. The stock is currently trading well below its 52-week high, having declined over the recent quarter, while the company remains unprofitable with significant operating losses. What makes this sale notable is Marshall's own track record at this company: all five of his prior open-market sales at Vera have been followed by stock declines, suggesting he has demonstrated consistent skill at timing exits before downward pressure. This is his sixth and seventh open-market sale at Vera in the past three years, continuing a pattern of steady, well-timed dispositions rather than panic selling or one-off exits. However, the underlying fundamentals remain weak—the company is not profitable, and the cumulative losses suggest significant operational challenges ahead.

CEO Fordyce Marshall sold 22,951 shares (23.0K) for $1.0M at $44.05 avg on 2026-04-14; follows consistent pattern of well-timed exits at VERA.

Fordyce Marshall, President and CEO of VERA, executed 3 separate sales totaling 22,951 shares for $1,011,050.81 on 2026-04-14, reducing his holdings by 8.9% to 235,244 shares. His prior 4 measurable sales at VERA all showed negative 90-day returns (ranging -2.9% to -55.1%), indicating a consistent pattern of selling before subsequent declines. This latest sale occurs with the stock trading 22.0% below its 52-week high and follows a +8.5% 30-day rally, potentially capturing a peak in recent price momentum. The company reported a net loss of $-80,293,000 for its most recent fiscal year, adding context to why disciplined exit execution may be relevant for a key executive holder.

VERA CEO Fordyce Marshall sold 16,925 shares at $41.98 on 2026-02-23; his prior 5 trades at this ticker show 100% well-timed 90d outcomes averaging -30.6% decline.

Fordyce Marshall, President and CEO of Vera Therapeutics, sold 16,925 shares (6.2% of his pre-transaction holdings) for $710,577.51. His trade history at this ticker is striking: all five prior sales occurred with subsequent 90-day declines (ranging from -29.6% to -55.1%), reflecting a 100% well-timed pattern at VERA. The current transaction occurs while the stock trades at $41.68, down 25.1% from its 52-week high of $55.67 and off 11.7% over the past month—yet near the midpoint of the 52-week range. More significantly, the company reported negative net income of $80.3M in its most recent full fiscal year, and with a market cap of $2.7B against substantial unprofitability, the fundamental backdrop is concerning. Marshall's consistent prior timing success at this ticker—combined with his execution during a period of weakness and negative earnings—warrants close monitoring of whether this sale precedes further deterioration.

VERA CEO Fordyce Marshall sold 19,688 shares for $546,913.71 across 3 sales in late Feb, retaining 204,665 shares post-sale.

Fordyce Marshall, President and CEO, executed 3 separate sales totaling 19,688 shares for $546,913.71 at blended average price $27.78 on 2025-02-21 and 2025-02-26. This represents an 8.8% reduction in his holdings, leaving him with 204,665 shares. The transaction occurred as the stock has declined 40.9% from its 52-week high of $49.75 and is trading 18.3% lower over the past 30 days alone. Vera is fundamentally unprofitable with net income of $-46,632,000 in its most recent fiscal year. Notably, Marshall's prior 5 sales at VERA (conducted in December 2024 and January 2025) showed negative returns at the 30-day mark (ranging from -13.0% to -23.3%), consistent with his broader cross-ticker track record of 100.00% well-timed sells at the 90-day horizon, though none of his same-ticker outcomes at VERA are yet measurable at 90 days.

CEO Fordyce Marshall sells 17,500 shares at blended avg $41.74 for $730,535.37; stock down -25.6% from 52-week high.

Fordyce Marshall, president and CEO of Vera Therapeutics, executed 3 separate sales on 2025-01-08 totaling 17,500 shares for $730,535.37, reducing his holdings by 10.9% to 143,603 shares. The sales occurred at a blended average price of $41.74, yet the stock currently trades at $37.02, down -25.6% from its 52-week high of $49.75 and -20.3% over the past 30 days. Vera is unprofitable with net income of -$46,632,000 over its most recent full fiscal year, and the company trades at a $2.3B market cap. Marshall's cross-ticker track record shows 20 prior open-market sells with an average 90-day return of -15.0%, while his 5 prior trades at VERA (all on 2024-12-18) remain unmeasurable to date. The timing of this sale relative to ongoing stock weakness warrants monitoring of whether the company's fundamental trajectory continues to deteriorate.

CEO Fordyce Marshall sold 17,500 shares (17.5K) across 5 transactions on 2024-12-18 for $753,679.56 at VERA

Fordyce Marshall, President and CEO of Vera Therapeutics, executed 5 separate sales totaling 17,500 shares for $753,679.56 on 2024-12-18, reducing his holdings by 10.9% to 143,603 shares. The sales occurred at prices ranging from $41.33 to $44.03 with a blended average of $43.07, compared to the current price of $42.60. Marshall's cross-ticker track record shows 20 prior sells with an average 30-day return of -6.7%, though his timing pattern across all tickers shows no well-timed exits at the 90-day mark. The company is unprofitable with net income of $-46,632,000.00 over its most recent full fiscal year, and the stock is trading -14.4% from its 52-week high following a -6.9% decline over the past 30 days. This transaction occurs during a period of stock weakness and within days of four additional sales by Marshall on 2024-12-11, suggesting sustained reduction of his equity exposure at the company.

CEO Fordyce Marshall sells 17,500 shares ($821.5K) at $46.94 blended price amid stock near 52-week high

Fordyce Marshall, President and CEO, executed 4 separate sales on 2024-12-11 totaling 17,500 shares for $821,523.29. The sales occurred at a blended average price of $46.94, near the stock's 52-week high of $49.75 (currently $44.05, down 10.9% in 30 days). The sale reduces his post-transaction holdings to 85,942 shares, representing a -16.9% reduction from pre-transaction holdings of 103,442 shares. This substantial reduction in the CEO's stake occurs while Vera Therapeutics remains unprofitable with net income of $-46,632,000.00 over the most recent full fiscal year. The timing of this large sale coincides with the stock near its elevated price levels, though without a 10b5-1 plan FLAG noted, scheduling versus discretionary intent cannot be determined from this filing alone.

Vera Therapeutics CEO Fordyce Marshall sells 19,375 shares for $929,560.27; -18.4% portfolio reduction near 52-week high ($48.83 vs $49.43).

Fordyce Marshall, Vera Therapeutics' President and CEO, executed 5 separate sales totaling 19,375 shares for $929,560.27 on 2024-11-25, reducing his holdings by 18.4% from 105,317 to 85,942 shares. The blended average sale price of $47.98 occurs near the stock's 52-week high of $49.43, with the current price at $48.83 representing -1.2% from that peak and a substantial 32.8% gain over 90 days. His prior cross-ticker track record shows 20 sells with an average 30-day return of 6.2%, but same-ticker history at VERA shows 5 recent sells on 2024-11-13 with outcomes not yet measurable; no same-ticker timing pattern can be evaluated. The company reported full-year net income of -$46.6M over its most recent fiscal year, adding fundamental context to an insider reduction near historically elevated valuations.

VERA CEO Fordyce Marshall sells 30,625 shares for $1.5M (9 separate transactions on 2024-11-13) at blended average $49.50; current price $46.26.

Fordyce Marshall, President and CEO of Vera Therapeutics, executed 9 separate sales totaling 30,625 shares for $1,516,037.41, reducing his holdings by 26.3% from 116,567 shares to 85,942 shares. The transactions occurred at prices ranging from $49.00 to $51.20 on 2024-11-13, notably above the current price of $46.26. Vera is unprofitable with a net income of $-46,632,000.00 over its most recent full fiscal year, and the stock's 30-day change shows +15.7% while remaining 6.4% below its 52-week high of $49.43. The scale of this disposal—a material reduction in CEO stake—coincides with the stock trading near its 52-week high and warrants investor attention regarding management's assessment of near-term value relative to fundamentals.